Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    Outskill Genai
    HomeNewsBusinessMarketsWockhardt's R&D prowess attracts marquee investors Madhusudan Kela, Prashant Jain

    Wockhardt's R&D prowess attracts marquee investors Madhusudan Kela, Prashant Jain

    Wockhardt has two molecules — Nafithromycin (WCK 4873) for treating pneumonia and WCK 5222 for urinary tract infection, in development phases, with launched lined up for FY25 and FY26

    Vaibhavi Ranjan
    March 28, 2024 / 13:04 IST
    Major institutions like ICICI Prudential, Mirae Asset, Tata Indian Opportunities Fund and others participated in Wockhardt's QIP.
    • PRO Panorama

      Moneycontrol Pro Panorama | The Great Energy Exodus: How AI Is Draining Capital from Big Oil

      Nov 3, 2025 / 03:03 PM IST

      In today’s edition of Pro Panorama: Auto sales in top gear, GAIL pumps it up, tax cloud over economic recovery, India’s Golden...

      Read Now
    Unlock This Article

    Are you a PRO subscriber? Sign In

    What Do You Get

    • Ad free Experience

      Seamless navigation, faster responses.

    • Expert Perspective

      Explore 230+ exclusive editorials every month

    • +

      Uncover Insights from World-Renowned Experts and Journalists

    • Actionable Insights

      40+ weekly investment ideas + 3 to 4 daily technical calls

    • Virtual Events

      Exclusive Live Webinars for Expert Trading & Investment Strategies!

    • Newsletters

      Stay ahead with daily and weekly insights

    View Offers

    Unlock exclusive discounts